Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection

Table 3 Univariate analysis of the clinical factors influencing the efficacy of moxifloxacin-containing triple therapy

Clinical factor	No. patients	Eradication rate	P value
Age, yr
≤ 60	60	61.7%	0.497
> 60	38	68.4%
Sex
Female	47	66.0%	0.740
Male	51	62.7%
Alcohol
No	81	65.4%	0.605
Yes	17	58.8%
Smoking
No	90	64.4%	1.000
Yes	8	62.5%
Hypertension
No	77	63.6%	0.797
Yes	21	66.7%
Diabetes
No	91	62.6%	0.416
Yes	7	85.7%
Gastric ulcer
No	92	64.1%	1.000
Yes	6	66.7%
Duodenal ulcer
No	83	63.9%	0.834
Yes	15	66.7%
First regimen
10-d ST	30	50.0%	0.138
2-wk ST	25	68.0%
2-wk CT	43	72.1%
Second regimen
1-wk MCT	60	56.7%	0.048
2-wk MCT	38	76.3%

ST: Sequential therapy; CT: Concomitant therapy; MCT: Moxifloxacin-containing triple therapy.